PreludeDx to Present New Data on the Clinical Utility of DCISionRT in Australian Patients with DCIS at the 2023 San Antonio Breast Cancer Symposium In data presented at SABCS23, DCISionRT changed radiation therapy decisions in 41% of DCIS patients

PreludeDx to Present Data for a Novel Molecular Biosignature to Predict Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer at the 2023 San Antonio Breast Cancer Symposium PreludeDx to Present Data for a Novel Molecular Biosignature to Predict Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer at the 2023 SABCS

PreludeDx™ to Present Multiple Presentations at the 2023 San Antonio Breast Cancer Symposium PreludeDx today announced that data will be presented in two separate poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS).

UPDATE - PreludeDx Presents Risk Assessments for DCIS Patients Using Clinicopathologic-Based Models Like RTOG 9804 and MSKCC Compared to DCISionRT® LAGUNA HILLS, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study...

PreludeDx™ to Present New DCISionRT® Comparative Data in Oral Session at ASTRO 2023 Annual Meeting LAGUNA HILLS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it...